Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway

Biochemical Pharmacology

Volumn 84, Issue 1, 2012, Pages 59-67

  Hsu, Jui Ling ^a   Ho, Yunn Fang ^a   Li, Tsai Kun ^a   Chen, Ching Shih ^b   Hsu, Lih Ching ^a   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Camptothecin; DNA damage; Hormone refractory prostate cancer; Rottlerin; Topoisomerase I DNA cleavage complex

Indexed keywords

ATM PROTEIN; CAMPTOTHECIN; DNA TOPOISOMERASE; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE C DELTA; ROTTLERIN; SERINE; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE S PHASE; CELL STRESS; CHEMOSENSITIZATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA FRAGMENTATION; DNA REPAIR; DRUG POTENTIATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ACETOPHENONES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOPYRANS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN KINASE C-DELTA; RNA, SMALL INTERFERING; TOPOISOMERASE I INHIBITORS; TRANSFECTION;

EID: 84860668140     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.03.023     Document Type: Article

References (38)

1. F. Stavridi, E.M. Karapanagiotou, and K.N. Syrigos Targeted therapeutic approaches for hormone-refractory prostate cancer Cancer Treat Rev 36 2010 122 130
2. G. Di Lorenzo, R. Autorino, W.D. Figg, and S. De Placido Hormone-refractory prostate cancer: where are we going Drugs 67 2007 1109 1124
3. M.E. Reyland Protein kinase C isoforms: multi-functional regulators of cell life and death Front Biosci 14 2009 2386 2399
4. C. Brodie, and P.M. Blumberg Regulation of cell apoptosis by protein kinase C delta Apoptosis 8 2003 19 27
5. E.H. Kim, S.U. Kim, and K.S. Choi Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP Oncogene 24 2005 838 849
6. D.M. Tillman, K. Izeradjene, K.S. Szucs, L. Douglas, and J.A. Houghton Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C Cancer Res 63 2003 5118 5125
7. J.H. Lim, J.W. Park, S.H. Kim, Y.H. Choi, K.S. Choi, and T.K. Kwon Rottlerin induces pro-apoptotic endoplasmic reticulum stress through the protein kinase C-delta-independent pathway in human colon cancer cells Apoptosis 13 2008 1378 1385
8. J.H. Lim, J.W. Park, K.S. Choi, Y.B. Park, and T.K. Kwon Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells Carcinogenesis 30 2009 729 736
9. B.A. Teicher Next generation topoisomerase I inhibitors: rationale and biomarker strategies Biochem Pharmacol 75 2008 1262 1271
10. K. Avemann, R. Knippers, T. Koller, and J.M. Sogo Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks Mol Cell Biol 8 1988 3026 3034
11. Y. Pommier DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition Chem Rev 109 2009 2894 2902
12. S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K.W. Kohn, and M. Cushman Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I Cancer Res 63 2003 7428 7435
13. D.M. Reese, S. Tchekmedyian, Y. Chapman, D. Prager, and P.J. Rosen A phase II trial of irinotecan in hormone-refractory prostate cancer Invest New Drugs 16 1998 353 359
14. E.P. Jane, D.R. Premkumar, and I.F. Pollack Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells J Pharmacol Exp Ther 319 2006 1070 1080
15. T. Kurosu, K. Tsuji, A. Kida, T. Koyama, M. Yamamoto, and O. Miura Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta Oncogene 26 2007 2975 2987
16. J. Zhang, N. Liu, S. Liu, Y. Liu, and D. Zheng PKCdelta protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis J Cell Biochem 96 2005 522 532
17. J.R. Fan, A.L. Peng, H.C. Chen, S.C. Lo, T.H. Huang, and T.K. Li Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses DNA Repair (Amst) 7 2008 452 463
18. H.Z. Lee Protein kinase C involvement in aloe-emodin- and emodin-induced apoptosis in lung carcinoma cell Br J Pharmacol 134 2001 1093 1103
19. H. Flores-Rozas, Z. Kelman, F.B. Dean, Z.Q. Pan, J.W. Harper, and S.J. Elledge Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme Proc Natl Acad Sci USA 91 1994 8655 8659
20. M. Koike, Y. Yutoku, and A. Koike Accumulation of p21 proteins at DNA damage sites independent of p53 and core NHEJ factors following irradiation Biochem Biophys Res Commun 412 2011 39 43
21. F. Condorelli, P. Salomoni, S. Cotteret, V. Cesi, S.M. Srinivasula, and E.S. Alnemri Caspase cleavage enhances the apoptosis-inducing effects of BAD Mol Cell Biol 21 2001 3025 3036
22. M. Gschwendt, H.J. Müller, K. Kielbassa, R. Zang, W. Kittstein, and G. Rincke Rottlerin, a novel protein kinase inhibitor Biochem Biophys Res Commun 199 1994 93 98
23. S.P. Soltoff Rottlerin: an inappropriate and ineffective inhibitor of PKCδ Trends Pharmacol Sci 28 2007 453 458
24. M.A. Bjornsti, P. Benedetti, G.A. Viglianti, and J.C. Wang Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin Cancer Res 49 1989 6318 6323
25. L.C. Riches, A.M. Lynch, and N.J. Gooderham Early events in the mammalian response to DNA double-strand breaks Mutagenesis 23 2008 331 339
26. J. Smith, L.M. Tho, N. Xu, and D.A. Gillespie The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer Adv Cancer Res 108 2010 73 112
27. E. Kiselev, S. Deguire, A. Morrell, K. Agama, T.S. Dexheimer, and Y. Pommier 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents J Med Chem 54 2011 6106 6116
28. Q.D. You, Z.Y. Li, C.H. Huang, Q. Yang, X.J. Wang, and Q.L. Guo Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification J Med Chem 52 2009 5649 5661
29. C. Gongora, N. Vezzio-Vie, S. Tuduri, V. Denis, A. Causse, and C. Auzanneau New Topoisomerase I mutations are associated with resistance to camptothecin Mol Cancer 10 2011 64
30. M. Malik, and J.L. Nitiss DNA repair functions that control sensitivity to topoisomerase-targeting drugs Eukaryot Cell 3 2004 82 90
31. Y. Pommier, C. Redon, V.A. Rao, J.A. Seiler, O. Sordet, and H. Takemura Repair of and checkpoint response to topoisomerase I-mediated DNA damage Mutat Res 532 2003 173 203
32. S. Chatterjee, M.F. Cheng, D. Trivedi, S.J. Petzold, and N.A. Berger Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines Cancer Commun 1 1989 389 394
33. G. Capranico, J. Marinello, and L. Baranello Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity Biochim Biophys Acta 1806 2010 240 250
34. L. Baranello, D. Bertozzi, M.V. Fogli, Y. Pommier, and G. Capranico DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus Nucleic Acids Res 38 2010 159 171
35. S. Solier, J. Barb, B.R. Zeeberg, S. Varma, M.C. Ryan, and K.W. Kohn Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors Cancer Res 70 2010 8055 8065
36. J.B. Baell, and D.C. Huang Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs Biochem Pharmacol 64 2002 851 863
37. F.W. Peyerl, S. Dai, G.A. Murphy, F. Crawford, J. White, and P. Marrack Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex Cell Death Differ 14 2007 447 452
38. A.F. Taghiyev, N.V. Guseva, H. Harada, C.M. Knudson, O.W. Rokhlin, and M.B. Cohen Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP Mol Cancer Res 1 2003 500 507